PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24130050-0	2013	Tunicamycin potentiates cisplatin anticancer efficacy through the DPAGT1/Akt/ABCG2 pathway in mouse Xenograft models of human hepatocellular carcinoma.	Tunicamycin	0-11	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	77-82	
24130050-6	2013	The N-linked glycosylation (NLG) inhibitor tunicamycin dramatically reduced ABCG2 expression, altered its subcellular localization, and reversed its drug efflux effect in multiple hepatocellular carcinoma cell lines.	Tunicamycin	43-54	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	76-81	
24130050-8	2013	Tunicamycin combined with cisplatin (CDDP) inhibited proliferating cell nuclear antigen (PCNA) expression and increased the cleavage of PARP; this effect was partially rescued by the overexpression of ABCG2 or Akt-myr.	Tunicamycin	0-11	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	201-206	
24130050-11	2013	In summary, our results suggest that tunicamycin may reverse the drug resistance and improve the efficacy of combination treatments for hepatocellular carcinomas by targeting the DPAGT1/Akt/ABCG2 pathway.	Tunicamycin	37-48	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	190-195